Lawrence Fong, M.D., is a Professor of Medicine in the Division of Hematology/Oncology at the University of California, San Francisco. He is focused on developing immunotherapies for cancers including prostate, kidney, bladder, melanoma, and GI cancers. He has been involved in pre-clinical and clinical studies with sipuleucel-T and anti-CTLA4 antibodies. Dr. Fong currently leads a translational immunotherapy program at UCSF and also leads a research lab studying antigen-specific recognition of tumors in both mouse models and in patients. Current work includes developing biomarkers that are associated with clinical responses or side effects. Dr. Fong obtained his MD at Stanford, completed internal medicine training at University of Washington, and oncology fellowship at Stanford. He has served on multiple NIH study sections and committees including the NCI Investigational Drug Steering Committee (IDSC), and NCI Genitourinary Cancers Steering Committee (GUSC). He has served on the editorial board of the Journal of Clinical Oncology and currently is as a senior editor for Cancer Immunology Research.